Engineered to give you confidence and control over your cardiometabolic clinical study

Broad GLP-1 availability depletes treatment-naive pools and drives placebo-arm dropout, as patients who experience weight regain abandon trials for commercial alternatives. Investigators hesitate to enroll in placebo-controlled designs when effective options are commercially available. Screen failure rates rise as washout-required candidates refuse to pause therapies that are visibly working.

Stigma leads patients to conceal eating disorder behaviors during intake, which surfaces only during late-stage psychological evaluations. Sites invest in anthropometric and metabolic screening before discovering disqualifying comorbidities. This creates late screen failures, unpredictable conversion rates, and compromised baseline integrity from unreliable self-reported dietary data.

Patients randomized to placebo experience visible weight regain and abandon trials to resume GLP-1 therapies available commercially. This asymmetric attrition threatens statistical power and compromises long-term extension data. Sites must backfill continuously from unpredictable emergency referral networks, inflating operational budgets and extending timelines.

T2D patients with obesity phenotypes enroll seeking dual glycemic and weight-loss benefit. When allocated to placebo or weight-neutral arms, absence of visible phenotypic change prompts withdrawal to access GLP-1 therapies commercially. This asymmetric attrition compromises long-term endpoint powering and forces sites into continuous backfill that strains capacity.

Treatment sequencing diverges widely across healthcare systems, creating heterogeneous control arms and complicating comparator selection. Reconciling distinct patient journeys into a single protocol delays timelines, while divergent background therapy creates variable drug interaction profiles that force complex adverse event adjudication across a distributed site network.

Protocols mandating inadequate glycemic control within narrow HbA1c bounds while requiring stable background medication regimens catch a shrinking intersection of the T2D population. Progressive metabolic phenotypes experience fluctuations that displace them from stability windows, and sites conduct exhaustive chart reviews to verify prescription histories: extending timelines and driving screen failures.

Standard-of-care closed-loop delivery systems actively correct glucose excursions. Protocols requiring device disablement face high refusal and dropout rates. Permitting varied commercial devices generates proprietary data streams that are difficult to harmonize, creating noisy efficacy endpoints and data architecture complexity that compounds throughout the trial lifecycle.

Adults with gradual-onset T1D are routinely misclassified as T2D in primary care, receiving incorrect management before deterioration triggers reclassification. Prior exposure to excluded medications generates protocol exclusions, and fragmented care histories make manual chart screening unreliable. Identifying eligible patients requires reaching into primary care networks that lack research infrastructure.

Protocols requiring enrollment within a narrow post-diagnosis window overlap with the acute crisis of new diagnosis. Cognitively overloaded families decline research participation, and patients who might qualify age out of the eligibility window before reaching stability. Sites relying on established databases miss most incident cases entirely.

Mandated lifestyle counseling for both arms triggers behavioral changes that drive histological improvement in the placebo cohort. This inflated placebo response compresses the observable efficacy delta, requiring expanded sample sizes and extended timelines. Introducing commercial metabolic therapies mid-study compounds the confounding and erodes the comparative signal further.

Serial liver biopsies create enrollment bottlenecks as patients refuse repeat sampling, and divergent histological scoring frameworks produce interpretive variance between local investigators and central readers. Local investigators clear patients who are subsequently rejected on central read, generating late screen failures after significant site investment.

Participants with overlapping metabolic conditions abandon studies to pursue GLP-1 agonists for weight and diabetes management. Because liver disease remains largely asymptomatic, patients prioritize immediate treatment for visible comorbidities when randomized to placebo. Unapproved background therapy erodes the observable difference between arms and forces continuous backfill.

Triglyceride levels respond acutely to minor dietary intake and metabolic shifts. Patients who qualify at initial screening frequently fall outside the eligibility range by the baseline visit due to routine lifestyle variation. This biomarker instability drives high screen-to-randomization ratios and complicates separation of pharmacological effects from transient lifestyle shifts.

Monogenic and multifactorial chylomicronemia present with identical clinical markers but require distinct trial designs. Standard primary care settings rarely order genetic panels needed to differentiate etiology, making EHR pre-screening by diagnosis code unreliable. Sites face specialist bottlenecks that extend screening windows and drive screen failures when panels return negative.

Patients managing severe hypertriglyceridemia live with ongoing pancreatitis risk. Washout of existing standard-of-care therapies or placebo assignment creates psychological friction: abdominal discomfort triggers immediate withdrawal to seek active intervention. Fear-driven disengagement truncates longitudinal efficacy data and forces backfill through unpredictable emergency referral networks.

WHO and ADA diagnostic criteria define prediabetes at different glycemic thresholds, creating classification problems in multinational trials. Community practices rely on routine HbA1c while protocols require glucose-loading tests that primary care lacks infrastructure to perform. This mismatch inflates feasibility estimates and restricts viable sites to specialized research units.

OGTT-based eligibility contrasts with routine non-fasting HbA1c standard in community care, subjecting asymptomatic patients to prolonged fasting and repeated blood draws. The substantial coefficient of variation in glucose results between visits in the same patient further compounds the problem for an already narrow glycemic eligibility window.

Patients with early dysglycemia feel entirely well, creating a persistent disconnect between lived experience and the procedural intensity trials demand. Repeated glucose tolerance tests, serial phlebotomies, and weight-stability run-in periods drive mid-study disengagement. Apathy-driven withdrawal degrades longitudinal data completeness and compromises primary endpoint evaluability.